Table 2 Special considerations for the management of hypertension in patients undergoing targeted therapy
From: Risks and management of hypertension in cancer patients undergoing targeted therapy: a review
Targeted therapy drug class | Preferred choice | Might be helpful | Drugs need to avoid |
|---|---|---|---|
VEGF inhibitors - VEGF antibody - TKI | ACEI/ARB Dihydropyridine calcium channel blocker | Nitrates | Avoid non-dihydropyridine calcium channel blocker for TKI users |
Androgen inhibitors - Abiraterone - Enzalutamide | Eplerenone for abiraterone | Dihydropyridine calcium channel blocker | Avoid spironolactone for abiraterone |
Proteasome inhibitors (carlifilzomib) | ACEI/ARB Beta-blocker | - | - |
PI3K inhibitor | - | ACEI/ARB | - |
Oral Bruton’s tyrosine kinase inhibitor | Beta-blocker | - | Avoid non-dihydropyridine calcium channel blocker. Avoid medications that potentially can increase heart rate. |